These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36107443)

  • 1. Factors Affecting Drug Exposure after Inhalation.
    Nováková A; Šíma M; Slanař O
    Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.
    Borghardt JM; Kloft C; Sharma A
    Can Respir J; 2018; 2018():2732017. PubMed ID: 30018677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs.
    Matera MG; Calzetta L; Ora J; Rogliani P; Cazzola M
    Expert Opin Drug Deliv; 2021 Jul; 18(7):891-906. PubMed ID: 33412922
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
    Hu X; Yang FF; Liao YH
    Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.
    Borghardt JM; Weber B; Staab A; Kloft C
    AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.
    Yong J; Shu H; Zhang X; Yang K; Luo G; Yu L; Li J; Huang H
    Int J Nanomedicine; 2024; 19():1723-1748. PubMed ID: 38414528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters.
    Dong L; Zhuang X
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the diseased lung microenvironment on the in vivo fate of inhaled particles.
    Gai J; Liu L; Zhang X; Guan J; Mao S
    Drug Discov Today; 2024 Jul; 29(7):104019. PubMed ID: 38729235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing and advancing dry powder inhalation towards enhanced therapeutics.
    Stegemann S; Kopp S; Borchard G; Shah VP; Senel S; Dubey R; Urbanetz N; Cittero M; Schoubben A; Hippchen C; Cade D; Fuglsang A; Morais J; Borgström L; Farshi F; Seyfang KH; Hermann R; van de Putte A; Klebovich I; Hincal A
    Eur J Pharm Sci; 2013 Jan; 48(1-2):181-94. PubMed ID: 23142635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspectives on pulmonary systemic and macromolecular delivery.
    Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges.
    Ruge CA; Kirch J; Lehr CM
    Lancet Respir Med; 2013 Jul; 1(5):402-13. PubMed ID: 24429205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation.
    Sosnowski TR
    Curr Pharm Des; 2016; 22(17):2453-62. PubMed ID: 26818874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of microparticles for pulmonary administration.
    Jain H; Bairagi A; Srivastava S; Singh SB; Mehra NK
    Drug Discov Today; 2020 Oct; 25(10):1865-1872. PubMed ID: 32712311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
    Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
    Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of pulmonary surfactant on nanoparticulate drug delivery systems.
    Schleh C; Rothen-Rutishauser B; Kreyling WG
    Eur J Pharm Biopharm; 2011 Apr; 77(3):350-2. PubMed ID: 21195761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary drug delivery: medicines for inhalation.
    Henning A; Hein S; Schneider M; Bur M; Lehr CM
    Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.